Erythropoietin/EPO Antibody (971007) [Unconjugated]

Erythropoietin/EPO was detected in immersion fixed paraffin-embedded sections of human liver using Mouse Anti-Human Erythropoietin/EPO Monoclonal Antibody (Catalog # MAB2873) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in hepatocytes. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

• Reactivity: Hu
• Applications: IHC
• Clone: 971007
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Erythropoietin/EPO Antibody (971007) [Unconjugated] Summary

• Immunogen: Chinese Hamster Ovary cell line, CHO-derived human Erythropoietin/EPO protein
  Ala28-Arg193
  Accession # CAA26094
• Specificity: Detects human Erythropoietin/EPO in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Erythropoietin/EPO Antibody (971007) [Unconjugated]

• ECYT5
• EP
• EPO
• epoetin
• Erythropoietin
• MGC138142
• MVCD2

Background

Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin (1). Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species (2, 3). Glycosylation of EPO is required for biological activities in vivo (4). Mature human EPO shares 75%-84% amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat EPO. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules (5). It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain (6-8). EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the EPO receptor (EPO R) (8, 9). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells (7, 8, 10, 11). Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation (1, 12). Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce EPO production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha (1, 6). EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis (7, 8, 13).

1. Koury, M.J. (2005) Exp. Hematol. 33:1263.
2. Jacobs, K. et al. (1985) Nature 313:806.
3. Wen, D. et al. (1993) Blood 82:1507.
4. Tsuda E., et al. (1990) Eur. J. Biochem. 188:405.
5. Lacombe, C. et al. (1988) J. Clin. Invest. 81:620.
6. Eckardt, K.U. and A. Kurtz (2005) Eur. J. Clin. Invest. 35 Suppl. 3:13.
7. Sharples, E.J. et al. (2006) Curr. Opin. Pharmacol. 6:184.
8. Rossert, J. and K. Eckardt (2005) Nephrol. Dial. Transplant 20:1025.
9. Koury, M.J. and M.C. Bondurant (1990) Science 248:378.
10. Acs, G. et al. (2001) Cancer Res. 61:3561.
11. Hardee, M.E. et al. (2006) Clin. Cancer Res. 12:332.
12. Verdier, F. et al. (2000) J. Biol. Chem. 275:18375.
13. Kertesz, N. et al. (2004) Dev. Biol. 276:101.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • CAA26094()